Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorGlobeNewsWire • 12/04/23
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialGlobeNewsWire • 11/20/23
Atossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3QProactive Investors • 11/13/23
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Atossa Therapeutics adds experienced finance exec to board of directorsProactive Investors • 11/09/23
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of DirectorsGlobeNewsWire • 11/09/23
Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situProactive Investors • 10/30/23
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini GroupPRNewsWire • 10/30/23
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades laterPRNewsWire • 10/11/23
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And TreatmentAccesswire • 09/18/23
Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higherProactive Investors • 09/08/23
Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral EndoxifenProactive Investors • 08/23/23
Atossa Therapeutics has analysts bullish as it advances breast cancer therapeuticProactive Investors • 08/14/23
Atossa Therapeutics rides strong momentum in 2Q to clinical advancements and corporate expansionProactive Investors • 08/14/23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023GlobeNewsWire • 08/08/23
Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in CanadaProactive Investors • 07/20/23
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in CanadaGlobeNewsWire • 07/20/23
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate DiagnosisAccesswire • 07/12/23
Atossa Therapeutics provides update on Phase 2 breast density trial enrollmentProactive Investors • 07/10/23
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical TrialGlobeNewsWire • 07/10/23